Hemophilia Therapeutics Pipeline Analysis 2017 - Designation and Other Developments

The hemophilia therapeutics pipeline is expected to grow in future due to rise in prevalence of genetic variation. Hemophilia which is symptomatized by excessive bleeding in brains, joints, nose and mouth. Some of the drivers for the growth of the hemophilia therapeutics pipeline include increasing incidence of hemophilia, less number of drugs present for treatment of hemophilia.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis

Hemophilia is the disease, mostly inherited, in which people have little or no clotting factor. Clotting factor is required for normal blood clotting. These proteins work with platelets to promote the clotting of the blood. There are two types of hemophilia. Hemophilia A, in which clotting factor VIII is missing or present in very low level. Hemophilia B, in which clotting factor IX is missing or present in very low levels.

Many institutes or associations and companies are collaborating for developing therapeutics for hemophilia. Wyeth Pharmaceuticals is in research collaboration and license agreement with Nautilus Biotech SA for development of recombinant Factor IX proteins for treatment of hemophilia. Spark therapeutics is developing a late gene therapy in collaboration with Pfizer, Inc. Baxter International Inc. is collaborating with Chatham Therapeutics, LLC for the development and commercialization of treatment of haemophilia A.

Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the key players having a pipeline of hemophilia therapeutics include Shire Plc, Biogen, Pfizer Inc., Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Biotest AG, Kedrion Biopharma Inc., and Octapharma AG.